Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC)
Authors
Solomon, B. J.Bauer, T. M.
Felip, E.
Liu, G.
Mazieres, J.
De Marinis, F.
Goto, Y.
Kim, D. W.
Laktionov, K. K.
Blackhall, Fiona H
Dall'O, E.
Polli, A.
Toffalorio, F.
Mok, T. S. K.
Affiliation
Department of Medical Oncology and Research Division, Peter MacCallum Cancer Centre & Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, AustraliaIssue Date
2022
Metadata
Show full item recordCitation
Solomon BJ, Bauer TM, Felip E, Liu G, Mazieres J, De Marinis F, et al. Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302255.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.9069Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9069Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.9069